-
公开(公告)号：EP3212182B1
公开(公告)日：2019-06-26
申请号：EP15787128.6
申请日：2015-10-27
IPC分类号： A61K31/295 , A61K31/721 , A61P7/06
-
2.发明公开IRON CARBOHYDRATE COMPLEX FOR TREATMENT OF IRON DEFICIENCY OF A FETUS OR AN INFANT 审中-公开用于治疗胎儿或婴儿缺铁症的铁碳水化合物复合物
公开(公告)号：EP3310364A1
公开(公告)日：2018-04-25
申请号：EP16734179.1
申请日：2016-06-22
摘要： Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：EP1492821A1
公开(公告)日：2005-01-05
申请号：EP03746252.0
申请日：2003-04-08
IPC分类号： C08B30/18 , A61K33/26 , A61K31/715 , A61P7/06
CPC分类号： C08B30/18 , A61K31/715 , A61K33/26 , A61K2300/00
摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10 % fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90 % of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10 % fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
-
4.发明公开
公开(公告)号：EP3925443A1
公开(公告)日：2021-12-22
申请号：EP21160316.2
申请日：2013-11-29
发明人： ANDREASEN, Hans Berg , CHRISTENSEN, Lars , NORDFJELD, Kim , SKYTTE, Jeppe , CLAUSEN, Christian , HOLST, Björn
IPC分类号： A01N1/02
摘要： The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.
-
公开(公告)号：EP2411053A1
公开(公告)日：2012-02-01
申请号：EP09776213.2
申请日：2009-03-25
发明人： ANDREASEN, Hans
CPC分类号： C08B37/0021 , A61K47/26 , C07H3/06
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9 % by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
6.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B2
公开(公告)日：2008-12-10
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
7.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B1
公开(公告)日：2002-07-17
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
公开(公告)号：EP3908289A1
公开(公告)日：2021-11-17
申请号：EP20705259.8
申请日：2020-02-10
-
9.发明公开IRON CARBOHYDRATE COMPLEX FOR TREATMENT OF RESTLESS LEG SYNDROME (RLS) 审中-公开用于治疗无症状腿综合征（RLS）的铁碳水化合物复合物
公开(公告)号：EP3270935A1
公开(公告)日：2018-01-24
申请号：EP16713771.0
申请日：2016-03-17
摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, or pallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
-
10.发明公开AN OLIGOSACCHARIDE AND A PROCESS FOR PREPARATION THEREOF 审中-公开VIGFAHREN ZUR HERSTELLUNG DAVON的OLIGOSACCHARID
公开(公告)号：EP3156075A1
公开(公告)日：2017-04-19
申请号：EP16201189.4
申请日：2009-03-25
发明人： ANDREASEN, Hans
CPC分类号： C08B37/0021 , A61K47/26 , C07H3/06
摘要： The invention relates to an oligosaccharide having a weight average molecular weight (Mw) of less than 3,000 Daltons, wherein said oligosaccharide comprises functional aldehyde groups and has a dimer saccharide content of 2.9 % by weight or less, based on the total weight of the hydrogenated oligosaccharide. The invention also relates to a process for preparing the oligosaccharide, which process comprises the steps of: hydrolysing a polysaccharide so as to reduce its molecular weight, wherein the resulting oligosaccharide comprises functional aldehyde groups, and fractioning the oligosaccharide according to molecular weight, so that the purified fraction has a weight average molecular weight equal to or less than 3,000 Daltons. The procedure of purification is performed by one or more membrane processes, having a cut-off value between 340 and 800 Daltons, which procedure is continued until the content of dimer saccharide in the purified fraction of oligosaccharide has been reduced to 2.9 % by weight or less, based on the total weight of the hydrogenated oligosaccharide.
摘要翻译： 本发明涉及重均分子量（Mw）小于3,000道尔顿的寡糖，其中所述寡糖包含官能醛基，二聚糖含量为2.9重量％以下，基于氢化物的总重量 寡糖。 本发明还涉及制备寡糖的方法，该方法包括以下步骤：水解多糖以降低其分子量，其中所得寡糖包含官能醛基，并根据分子量对寡糖进行分级，使得 纯化级分的重均分子量等于或小于3,000道尔顿。 纯化的过程通过一个或多个膜过程进行，其截止值在340和800道尔顿之间，该过程继续进行，直到寡糖的纯化级分中的二聚体糖的含量已经降至2.9重量％，或 较少，基于氢化寡糖的总重量。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.01 秒)
